About Us

Trevigen, Inc. is a rapidly growing biotechnology company focused on the development of products and technology for cancer research, emphasizing apoptosis, DNA damage and repair, and cancer cell function and behavior. The company is located in the I-270 "High technology Corridor" in Gaithersburg, Maryland. Trevigen-brand research products are marketed via the Internet, catalog, journal advertising, direct mail, and telemarketing, giving Trevigen worldwide recognition among those in the area of cancer research. Distributor appointments have been made in the Americas, Europe, and the Pacific Rim. Trevigen also has in place supply agreements with major government and university medical research centers in order to make us a part of the growing areas of government research and pharmaceutical research. The company is the recipient of several SBIR grants from the National Institutes of Health, concerning technology development for the analysis of DNA damage.

Trevigen is more than a typical biotechnology company. We are a long-standing provider of quality reagents and kits for researchers investigating programmed cell death and DNA damage and repair. With the increasing attention being placed on cell death and its role in cancer research, we are pleased to continue to support the growing numbers of investigators moving into these overlapping fields of research. A logical extension of our focus on cancer research has been the recent development of assays for cancer cell function and behavior including angiogenesis, cell invasion and tumor formation.

Trevigen Cell Assays, (TCA) a division of Trevigen, Inc., was established in 2008 to conduct contract research work for the pharmaceutical, biotechnology, government and academic segments of the research market. TCA specializes in designing and conducting assays for lead compound and genotoxic screening based on DNA damage and repair and cancer cell behavior. We are proud of the role that we play in pharmaceutical research and government research.

Choosing a biotechnology company that you can rely on for the products you need to study cell death in cancer research is important. Our role in pharmaceutical research and government research are one phase of what we do. We are also here to provide the quality reagents and biotechnology equipment to those small or individual facilities that are taking an active role in studying DNA damage, cell death, and cancer cell behavior.

Our website contains many new products which you can find at a glance in the "New Products" Products section. As always, Trevigen brand products are manufactured to the highest standards of quality and backed by expert technical support. We know the importance of providing these important biotechnology products with quality that exceeds industry standards. Our reputation as a biotechnology company is important to us and we strive to always maintain an inventory of those products which provide the highest levels of performance in cancer research.

Trevigen Collaborations

In our efforts to provide our customers with products that reflect state of the art technology, we have developed collaborations with leading scientists and biotechnology companies in the scientific community. Members of our biotechnology company and those that we collaborate with are among some of the most qualified specialists in the field of cancer research.

Robert Sobol, Ph.D. 

Dr. Sobol is a member of both the Molecular and Cellular Biology Program and the Brain Tumor Program at the University of Pittsburgh Cancer Institute (UPCI) and holds an academic appointment in the Department of Pharmacology & Chemical Biology at the University of Pittsburgh, School of Medicine and a secondary appointment in the Department of Human Genetics (School of Public Health) as Assistant Professor. In addition, Dr. Sobol is the Director of the UPCI Lentiviral Facility and co-Director of the UPCI Vector Core Facility. Research in the Sobol lab focuses on the mechanism of base excision repair, PARP and NAD+ metabolism in human cells and the convergent role of these enzymes and pathways in response to chemotherapy. Dr. Sobol is a collaborator for the development of knock down cell lines and unique DNA repair assays.

Bevin Engleward, Ph.D.

Dr. Engleward received her Ph.D. from Harvard and is now a tenured professor at MIT. Her work is focused on inflammatory chemicals and the interplay between inflammation, DNA repair and genomic stability. Since 2006, Bevin Engelward has participated in the development of the Chulabhorn Graduate Institute in Bangkok, Thailand, and she is currently affiliated with the Singapore MIT Alliance for Research and Technology (SMART). Dr. Engelward and her collaborators have worked to create an array based higher throughput DNA repair assay that can be used for basic research as well as epidemiology, drug discovery, and drug safety. The CometChip was developed as part of this effort. Her main objectives are to further our understanding of the molecular underpinnings of gene-environment interactions to provide new research tools. Ultimately it is hoped that this work will contribute toward improved public health.

Hynda Kleinman, Ph.D.

For several years, Trevigen has engaged the inventor of Basement Membrane Extract (BME), Dr. Hynda Kleinman, as a Science Advisor. In that capacity, Dr. Kleinman has recommended and critiqued the acquisition of raw materials, production strategy and stability, and performance testing for Cultrex BME. Her direction has been captured by “hands on” Ph.D. Senior Scientists and highly qualified technicians. In addition to her strategic advice on the production and qualification of BME, Dr. Kleinman freely interacts with Trevigen customers, giving advice on conducting experimental work, and formally lecturing in seminars and in webinars.